XML 29 R17.htm IDEA: XBRL DOCUMENT v2.4.0.6
Fair Value Measurements (Tables)
3 Months Ended
Mar. 31, 2013
Fair Value Measurements  
Schedule of assets measured at fair value on a recurring basis

We break down the inputs used to measure fair value for these assets at March 31, 2013 and December 31, 2012 as follows (in thousands):

 

 

 

At March 31,
2013

 

Quoted Prices in
Active Markets
(Level 1)

 

Significant Other
Observable
Inputs
(Level 2)

 

Significant
Unobservable
Inputs
(Level 3)

 

Cash equivalents (1)

 

$

96,072

 

$

91,072

 

$

5,000

 

$

—

 

Corporate debt securities (2)

 

205,098

 

—

 

205,098

 

—

 

Debt securities issued by U.S. government agencies (2)

 

24,939

 

—

 

24,939

 

—

 

Debt securities issued by the U.S. Treasury (2)

 

13,424

 

13,424

 

—

 

—

 

Debt securities issued by states of the United States and political subdivisions of the states (2)

 

20,800

 

—

 

20,800

 

—

 

Investment in Regulus Therapeutics Inc.

 

44,863

 

—

 

—

 

44,863

 

Equity securities (3)

 

2,619

 

2,619

 

—

 

—

 

Total

 

$

407,815

 

$

107,115

 

$

255,837

 

$

44,863

 

 

 

 

At December 31,
2012

 

Quoted Prices in
Active Markets
(Level 1)

 

Significant Other
Observable
Inputs
(Level 2)

 

Significant
Unobservable
Inputs
(Level 3)

 

Cash equivalents (1)

 

$

105,496

 

$

101,496

 

$

4,000

 

$

—

 

Corporate debt securities (2)

 

193,507

 

—

 

193,507

 

—

 

Debt securities issued by U.S. government agencies (2)

 

18,108

 

—

 

18,108

 

—

 

Debt securities issued by the U.S. Treasury (2)

 

13,452

 

13,452

 

—

 

—

 

Debt securities issued by states of the United States and political subdivisions of the states (2)

 

24,897

 

—

 

24,897

 

—

 

Investment in Regulus Therapeutics Inc.

 

33,622

 

—

 

—

 

33,622

 

Equity securities (3)

 

4,874

 

4,146

 

—

 

728

 

Total

 

$

393,956

 

$

119,094

 

$

240,512

 

$

34,350

 

 

(1)         Included in cash and cash equivalents on our consolidated balance sheet.

 

(2)         Included in short-term investments on our consolidated balance sheet.

 

(3)         Included in other current assets on our consolidated balance sheet.

 

Summary of investments measured at fair value on a recurring basis using significant unobservable inputs (Level 3)

The following is a summary of our investments measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the three months ended March 31, 2013 (in thousands):

 

 

 

Investments

Valued Using

Level 3 Inputs

 

Balance at December 31, 2012

 

$

34,350

 

Total gains and losses:

 

 

 

Included in gain on investments

 

(1,163

)

Included in accumulated other comprehensive income (loss)

 

11,716

 

Cost basis of shares sold

 

(40

)

Balance at March 31, 2013

 

$

44,863